Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-DLL3/CD3 bispecific antibody QLS31904

A bispecific antibody directed against both the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-DLL3/CD3 bispecific antibody QLS31904 binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the DLL3 antigen on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.
Synonym:anti-DLL3/anti-CD3 bispecific antibody QLS31904
DLL3 x CD3 bispecific antibody QLS31904
Code name:QLS 31904
QLS-31904
QLS31904
Search NCI's Drug Dictionary